These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 27638929)
1. Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy. Ardill JE; Johnston BT; McCance DR; Eatock M Ann Clin Biochem; 2017 Mar; 54(2):297-301. PubMed ID: 27638929 [TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine tumours of the small intestine. Strosberg J Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):755-73. PubMed ID: 23582917 [TBL] [Abstract][Full Text] [Related]
3. Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis. Ardill JE; McCance DR; Stronge WV; Johnston BT Ann Clin Biochem; 2016 Mar; 53(Pt 2):259-64. PubMed ID: 26038607 [TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A. Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268 [TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548 [TBL] [Abstract][Full Text] [Related]
6. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667 [TBL] [Abstract][Full Text] [Related]
7. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy. Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018 [TBL] [Abstract][Full Text] [Related]
8. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel. Woltering EA; Voros BA; Thiagarajan R; Beyer DT; Ramirez RA; Wang YZ; Mamikunian G; Boudreaux JP Pancreas; 2018 Aug; 47(7):843-848. PubMed ID: 29939909 [TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327 [TBL] [Abstract][Full Text] [Related]
11. [Neuroendocrine tumors of gastrointestinal tract in own material]. Myśliwiec P; Gryko M; Kedra B; Zalewski B; Kowalska I; Myśliwiec J Endokrynol Pol; 2006; 57(2):166-71. PubMed ID: 16773593 [TBL] [Abstract][Full Text] [Related]
12. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up]. Igaz P; Rácz K; Tulassay Z Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114 [TBL] [Abstract][Full Text] [Related]
13. A jejunal stromal tumour in a patient with metastatic neuroendocrine cancer of unknown origin; a rare coexistence, diagnostic and therapeutic challenge. El Ali Z; Iwanik K; Sowiński J; Swora E; Grzymislawski M Endokrynol Pol; 2009; 60(3):216-20. PubMed ID: 19569023 [TBL] [Abstract][Full Text] [Related]
15. Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms. Diebold AE; Boudreaux JP; Wang YZ; Anthony LB; Uhlhorn AP; Ryan P; Mamikunian P; Mamikunian G; Woltering EA Surgery; 2012 Dec; 152(6):1172-6. PubMed ID: 23102678 [TBL] [Abstract][Full Text] [Related]
16. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024 [TBL] [Abstract][Full Text] [Related]
17. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). de Herder WW Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895 [TBL] [Abstract][Full Text] [Related]
18. Malignant carcinoid in two brothers. Kinova S; Duris I; Kovacova E; Stvrtina S; Galbavy S; Makaiova I Bratisl Lek Listy; 2001; 102(5):231-4. PubMed ID: 11725374 [TBL] [Abstract][Full Text] [Related]
19. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016 [TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action. Imam H; Gobl A; Eriksson B; Oberg K Anticancer Res; 1997; 17(6D):4659-65. PubMed ID: 9494585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]